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Abstract
Background: Previous clinical efficacy trials failed to support the continued development of recombinant gp120 (rgp120) as
a candidate HIV vaccine. However, the recent RV144 HIV vaccine trial in Thailand showed that a prime/boost immunization
strategy involving priming with canarypox vCP1521 followed by boosting with rgp120 could provide significant, although
modest, protection from HIV infection. Based on these results, there is renewed interest in the development of rgp120
based antigens for follow up vaccine trials, where this immunization approach can be applied to other cohorts at high risk
for HIV infection. Of particular interest are cohorts in Africa, India, and China that are infected with clade C viruses.
Methodology/Principal Findings: A panel of 10 clade C rgp120 envelope proteins was expressed in 293 cells, purified by
immunoaffinity chromatography, and used to immunize guinea pigs. The resulting sera were collected and analyzed in
checkerboard experiments for rgp120 binding, V3 peptide binding, and CD4 blocking activity. Virus neutralization studies
were carried out with two different assays and two different panels of clade C viruses. A high degree of cross reactivity
against clade C and clade B viruses and viral proteins was observed. Most, but not all of the immunogens tested elicited
antibodies that neutralized tier 1 clade B viruses, and some sera neutralized multiple clade C viruses. Immunization with
rgp120 from the CN97001 strain of HIV appeared to elicit higher cross neutralizing antibody titers than the other antigens
tested.
Conclusions/Significance: While all of the clade C antigens tested were immunogenic, some were more effective than
others in eliciting virus neutralizing antibodies. Neutralization titers did not correlate with rgp120 binding, V3 peptide
binding, or CD4 blocking activity. CN97001 rgp120 elicited the highest level of neutralizing antibodies, and should be
considered for further HIV vaccine development studies.
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Introduction
The development of a vaccine to prevent HIV infection is
a global health priority. After more than 25 years of research, a
modest level of protection was recently achieved in humans in a
Phase 3 HIV-1 vaccine trial (RV144) involving more than 16,000
subjects in Thailand [1]. The RV144 study entailed priming
immunizations with a recombinant canarypox vector (vCP1521)
containing HIV env and gag genes to elicit cellular immune
responses [2]. This was followed by booster immunizations with a
bivalent rgp120 subunit vaccine, AIDSVAX B/E [3–5], to elicit
antibody responses. The results of this trial were surprising because
previous studies showed that these vaccines, given alone, were
unable to elicit consistent T cell responses [6] or protective anti-
body responses [7,8]. Indeed, as a result of these studies, product
development efforts on both rgp120-based vaccines and canar-
ypox virus-based vaccines were largely discontinued, and efforts
were refocused on adenovirus-based vaccines [9] and trimeric
envelope glycoprotein vaccines [10,11]. However, the results from
the RV144 trial have rekindled interest in both rgp120 subunit
vaccines and canarypox virus vectors. There is now strong interest
in confirmatory clinical studies with similar rgp120 vaccines and
recombinant pox virus vectors designed for regions of the world
where different clades (subtypes) of HIV are in circulation.
Because it is desirable to match the genetic clade of vaccine
immunogens to the viruses circulating in clinical cohorts, the
AIDSVAX B/E rgp120 vaccine used in Thailand in the RV144
trial is considered inappropriate for clinical trials in Africa, India,
or China, where clade C viruses account for the majority of new
infections (UNAIDS, http://www.unaids.org). As a consequence,
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12076there is new interest in clade C rgp120 vaccines. These studies
represent the only comparative immunogenicity of clade C
rgp120s with diverse amino acid sequences, prepared in a manner
identical to the envelope immunogens used in the AIDSVAX B/E
vaccine. Here we compare the magnitude and specificity of
functionally significant antibody responses to clade C rgp120 anti-
gens. These results may be useful in the selection of clade C
vaccine antigens that could potentially be used in clinical develop-
ment studies designed to repeat the RV144 prime/boost immu-
nization regimen.
Results
In considering the development of clade C vaccine immuno-
gens, we wanted to encompass the range of sequence variation
found in clade C envelope proteins from different regions of the
world. For this purpose, we assembled a collection of ten clade C
envelope genes with diverse sequences. The final collection
included one isolate from Zambia, two each from China, India,
and Tanzania, and three from South Africa (Table 1). An
alignment of the amino acid sequences of these strains is provided
in supplemental Figure S1. A pairwise comparison of protein
sequence homology is provided in Table 2. A phylogenetic analysis
of the HIV envelope protein rgp120 used in this study along with a
diverse collection of clade C virus reference sequences from the
panel of Li et al. [12] and the Los Alamos HIV sequence database
(www.hiv.lanl.gov/.webloc) are provided in Figure S2. It can be
seen that the viruses selected for protein expression studies are well
distributed throughout the phylogeny and do not form unrepre-
sentative clusters. However, the relevance of phylogenetic trees
with respect to protective immune responses is uncertain. For this
reason we were also interested in carrying out phylogenetic
analysis of domains containing important neutralizing epitopes
such as the V3 domain [13]. The results provided in Figure S3 and
Table S1 show a high level of V3 sequence diversity within the
panel of viruses studied.
All 10 envelope genes were then expressed in mammalian cells
and purified for immunization studies. The mobility and purity of
the purified envelope proteins by SDS-polyacrylamide gel
chromatography is shown in Figure 1. The envelope proteins
were found to be free of proteolysis products and greater than 98%
pure as indicated by silver staining. Groups of 7 guinea pigs were
immunized with each of the 10 clade antigens as described in the
Materials and Methods section. In addition, two groups of animals
were immunized with MN-rgp120 and A244-rgp120 that were
included in the AIDSVAX B/E vaccine [3,4]. This vaccine was
used in the Phase I/II and Phase III clinical trials alone [5,7] and
in connection with vCP1521 in the RV144 clinical trial [1].
Initially, we measured the binding of the resulting antibodies to
homologous and heterologous rgp120 by the same ELISA assay
(supplemental Figure S4) described previously [14]. We found that
all of the antigens were immunogenic and elicited high levels of
antibodies similar to those described previously [15]. We then
examined the cross reactivity of each serum pool with rgp120s
from clade C (ZM651), clade B (MN), clade E (CM244), and clade
D (Z6) strains of HIV (Figure S4). Each of the clade C serum pools
exhibited a high level of cross reactivity with envelope proteins
from different clades; however, the magnitude of the immune
response to the ZM651 protein was somewhat greater than that of
the other immunogens. This level of cross reactivity was not
unexpected, since previous studies also showed a high degree of
cross reactivity of antisera to rgp120 with envelope proteins from
CCR5 and CXCR4 viruses of different clades [3,16].
We next examined the formation of antibodies to the V3
domain, which is known to contain important neutralizing
epitopes [17]. The sequence of the synthetic peptides used in
these assays is provided in supplemental Table S1. Large
differences were observed in the magnitude and specificity of the
V3 antibody response elicited by different clade C immunogens
(Figure 2). For example, antibodies to both the ZM651 and
TZ97002 envelope proteins elicited a high level of cross reactivity
with the V3 peptides from clade C and clade A peptides, but poor
reactivity with the clade D V3 peptide. Many of the clade C pools
reacted with the clade B V3 peptide and a few reacted with the
clade E V3 peptide. Significantly, antisera to MN-rgp120 and
A244-rgp120 exhibited poor cross reactivity with clade C V3
peptides, demonstrating that while antibodies to clade C
immunogens are able to bind to clade B and E V3 peptides, the
reverse is not true. These studies suggest that immunization with
vaccines containing MN- and A244-rgp120s (e.g. AIDSVAX B/E)
would not be effective in eliciting antibodies to the V3 domain of
clade C viruses.
We next examined the ability of the clade C sera to inhibit the
binding of rgp120 to soluble CD4 (Table 3). All of the envelopes
tested elicited antibodies able to block the binding of rgp120 to
CD4. As expected, the highest level of inhibition was usually, but
not always, observed with homologous protein. However, there
appeared to be significant differences in the ability of different
immunogens to elicit CD4 blocking antibodies. For example, the
ZM651, IN98025, and IN98026 sera were less effective in
inhibiting the binding of heterologous envelopes to CD4 than
sera to most of the other antigens tested.
The ability of antisera from all 10 clade C antigens to neutralize
clade B and C viruses was measured in two different laboratories
using two different panels of viruses (Tables 4 and 5). In the first
assay (Table 4), pseudotype viruses were prepared from a panel of
10 heterologous clade C viruses and 4 clade B viruses, and used to
infect U87 cells transfected with CD4 and chemokine receptors
(U87 pseudotype assay)[18,19]. Interestingly, 8 of the 10 clade C
sera pools showed significant neutralization against laboratory-
adapted clade B viruses (e.g., MN and SF162) ,whereas the
prototypic clinical isolate, JRCSF, was resistant to neutralization.
This result confirmed the high level of cross reactivity of clade C
antisera against clade B viral proteins. When the neutralizing
activity against clade C clinical isolates was examined, significant
differences were seen among the sera elicited by different antigens.
Table 1. Listing of clade C viruses.
Strain Year collected Origin
CN97001 1997 China
CN98005 1998 China
IN98025 1998 India
IN98026 1998 India
TZ97005 1997 Tanzania
TZ97008 1997 Tanzania
ZA97002 1997 South Africa
ZA97010 1997 South Africa
ZA97012 1997 South Africa
ZM651 1996 Zambia
Clade C envelope genes were cloned from HIV infected cell lysates provided by
the joint United Nations program on HIV/AIDS and the National Institutes of
Allergy and Infectious Diseases, NIH. Viruses were selected on the basis of
geographical diversity as well as variation in V3 domain sequences.
doi:10.1371/journal.pone.0012076.t001
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envelopes showed the weakest neutralization titers and were
unable to neutralize any of the clade C viruses in the panel. In
contrast, the sera raised against the CN97001 and IN98026
envelope proteins neutralized multiple clade C viruses. While the
neutralization titers to these clade C envelopes were low, so were
the neutralization titers obtained with the positive control serum,
N16, from an HIV infected individual. This serum is known to
possess high levels of broadly neutralizing antibodies [20]. Thus
the viruses in this panel for the most part represented difficult to
neutralize viruses. The inclusion of the aMLV virus in the U87
pseudotype assay provided a reliable control, demonstrating that
the neutralization activity observed was not an artifact of a non-
specific immune response to viral membranes.
The same sera were then tested in a second assay (TZM-bl
assay) that included 6 clade C viruses and 2 clade B viruses. The
results obtained in this TZM-bl assay (Table 5) were qualitatively
similar to results obtained in the U87 pseudotype neutralization
assay described above. We observed that most of the clade C sera
were able to neutralize the clade B, laboratory adapted isolates,
MN and SF162. Both assays showed that the CN97001 and
IN98026 sera possessed the highest levels of neutralizing activity,
whereas the ZM651, IN98025 and ZA97012 sera exhibited the
lowest level of neutralizing activity.
Discussion
These studies demonstrated that envelope proteins from clade C
virus were all comparably immunogenic as measured by rgp120
binding; however, some were better than others in eliciting
antibodies able to bind to the V3 domain, or block the binding of
CD4 to rgp120. Most of the sera to clade C viruses were able to
neutralize tier 1 strains of clade B viruses, thus demonstrating
some level of cross clade neutralizing activity. This activity may
well be attributable to antibodies to the V3 domain of clade C
antigens which exhibited significant cross reactivity with clade B
V3 domain peptides. It is well known that antibodies to the V3
domain are particularly effective in neutralizing tier 1 viruses. As
has been described previously, there was poor neutralization of
clinical isolates of HIV-1. This continues to be a problem with all
of the candidate HIV vaccines tested to date [21,22]. Although it
has long been speculated that that trimeric forms of HV envelope
proteins would be better than monomeric rgp120 with respect to
eliciting antibodies able to neutralize clinical isolates, the results to
date have been equivocal [23].
Overall the antibody responses strains such as CN97001, and
IN98026 were similar to those seen with the envelope proteins
contained in the AIDSVAX B/E vaccine used in the RV144
clinical trial. However, other strains (e.g. ZM651, IN98025,
ZA97010, ZA97012) were significantly less effective in eliciting
neutralizing antibodies. We did not observe any significant
correlation between antibodies able to neutralize primary isolates
and any of the antibody binding assays. Multiple sera that pos-
sessed significant CD4 blocking titers failed to exhibit virus
neutralization; demonstrating that CD4 blocking antibodies to
rgp120 are not a correlate of virus neutralization. Thus, CD4
blocking antibodies elicited against gp120 immunogens appear to
differ from CD4 blocking antibodies present in sera from HIV-
infected individuals, where immunoadsorbtion studies have shown
that a significant proportion of broadly neutralizing antibodies
possess CD4 blocking activity [24,25]. Whether this difference
can be attributed to differences in antibody avidity or antibody
Table 2. Pairwise comparison of clade C rgp120 sequences.
ZM651 IN98025 IN98026 TZ97008 ZA97002 TZ97005 CN98005 ZA97010 CN97001 ZA97012
ZM651 * 78 77 77 78 79 77 77 77 75
I N 9 8 0 2 5 * 8 47 77 87 98 47 88 37 7
I N 9 8 0 2 6 * 7 97 88 08 57 98 57 8
TZ97008 * 79 79 78 79 78 78
ZA97002 * 78 78 78 77 78
TZ97005 * 7 97 78 07 7
CN98005 *7 7 8 9 7 7
ZA97010 *7 8 8 1
CN97001 *7 7
ZA97012 *
Amino acid sequences were deduced from the DNA sequences of the 10 clade C rgp120 genes. Pairs of sequences were aligned, and the percent identity between each
pair determined using the MacVector Sequence Analysis package (Accelrys Inc., San Diego, CA).
doi:10.1371/journal.pone.0012076.t002
Figure 1. SDS-PAGE showing purified subtype C rgp120
antigens. 10 different subtype C rgp120 isolate proteins were
expressed in 293 T cells and purified. 150ng of purified protein was
run on SDS PAGE gel and visualized by silver staining. Arrow indicates
mobility of molecular weight standard.
doi:10.1371/journal.pone.0012076.g001
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used to select the immunogens included in the AIDSVAX B/E
vaccine used in the RV144 trial (e.g. immunogenicity, neutralizing
activity, and common sequence polymorphisms at neutralizing
sites), rgp120 from the CN97001 strain of HIV-1, would be our
recommendation for a clade C immunogen to include in a subunit
boost in studies designed repeat the RV144 immunization regimen.
However, we don’t know if in vitro neutralization is a correlate of
protective immunity in humans. It is possible that antibodies with
activities distinct from those measured in these studies, might be
Figure 2. Binding of antisera against V3 peptides from subtypes C, A, B, E and D envelope proteins. ELISA plates were coated with 23-
mer V3 peptides corresponding to the subtype C isolates, as well as the sequence for V3 domain peptides from subtype A, B, E (crf A/E), and D
envelope glycoproteins. Antibody binding was measured at a 1:500 serum dilution as described previously [14]. The data bars correspond to the
following strains: ZM1, ZM651; IN1, IN98025; IN2, IN98026; TZ2, TZ97008; ZA1, ZA97002; TZ1, TZ97005; CN2, CN98005; ZA2, ZA97010; CN1, CN97001;
ZA3, ZA97012.
doi:10.1371/journal.pone.0012076.g002
Table 3. Blocking of CD4 binding to rgp120 by antisera against subtype C rgp120.
Antiserum
Coat ZM651 IN98025 IN98026 TZ97008 ZA97002 TZ97005 CN98005 ZA97010 CN97001 ZA97012
ZM651 67 39 55 71 76 83 67 77 77 54
IN98026 46 50 80 69 70 77 69 73 74 61
TZ97008 26 14 35 69 60 61 53 66 62 52
ZA97002 64 63 83 83 84 77 66 79 75 70
T Z 9 7 0 0 5 4 7 2 74 65 66 277 50 56 57 51
CN98005 47 39 55 59 64 68 76 68 70 57
ZA97010 32 30 48 72 72 64 58 91 70 62
CN97001 41 30 45 64 71 74 64 80 96 62
ZA97012 47 37 53 75 73 69 64 75 71 76
The ability of antibodies to inhibit the binding of CD4-IgG to rgp120 was measured using an assay similar to that described previously [14]. Briefly, rgp120 was captured
onto microtiter dishes. Sera were added at a 1:200 dilution in duplicate and incubated 2 hr, and soluble CD4 was then added without washing. The amount of bound
CD4 with and without added anti-rgp120 sera was monitored by the binding of HRP-labeled mouse monoclonal antibody to CD4. Results using rgp120 from the
IN98025 isolate were not available due to the inability of this envelope protein to bind CD4-IgG.
doi:10.1371/journal.pone.0012076.t003
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of the RV144 trial has indicated that protection was achieved in
the absence of high titers of neutralizing antibodies (D. Montefiori,
oral presentation, HVTN Full Group Meeting, Washington DC,
May 4–6, 2010). This result suggests that neutralization titers
lower than those that we are able to measure in the TZM-bl assay,
or that other types of antibody responses, such as those that
mediate antibody dependent cytotoxicity, or reduce virus mobility
at mucosal surfaces, might be better correlates of protective
immunity. However, until definitive results are available, the
correlates of protection remain undefined. The proteins described
in this paper provide the only comparative immunogenicity study
of clade C rgp120 vaccine antigens constructed in the same
manner as the clade B and clade E antigens used for booster
immunizations in the RV144 trial. Our results provide a rationale
for the selection of immunogens to be used in optimizing prime/
boost immunization regimens. Further studies focusing on
reactivity with viruses from specific clinical cohorts in which
RV144 follow-up trials would be carried out might provide further
rationale for the selection of specific immunogens.
Table 4. Neutralization of clade C and clade B viruses in the U87 pseudotype neutralization assay by antibodies to rgp120.
Antisera
Virus Clade ZM651 IN98025 IN98026 TN97008 ZA97002 TZ97005 CN98005 ZA97010 CN97001 ZA97012 N16
2 1 0 6 8C -- 2 71 22 11 3- - 5 0- 1 5 0
92ZW101 C - - 24 - - 12 - - 66 - 233
93IN101 C - - 18 - 12 - - - - - 37
93IN999 C - - - - - - - - - - 72
93MW960 C - - 33 20 21 - 44 - 79 - 270
97ZA102 C - - - - - - - - - - 45
98BR004 C - - - - - - - - - - 100
98CN006 C - - 18 - 14 14 - - 42 - 116
98CN009 C - - 19 - - - - - - - 60
98IN022 C - - 95 55 61 17 261 - 345 38 73
BAL B - - 33 52 13 - 68 - 430 - 683
J R C S F B - ---------2 1 1
MN B - - 1882 1669 355 202 2324 796 8863 36 3798
NL43 B - - 84 161 282 159 69 66 170 79 1510
SF162 B 183 - 3457 6669 579 1875 4403 3044 13437 197 7358
aMLV B ,10 11 ,10 ,10 ,10 ,10 14 20 ,10 ,10 ,10
Virus neutralization titers were measured in the U87 pseudotype virus neutralization assay [18,19]. Virus designations include the country of origin as follows: BR, Brazil;
CN, China; IN, India; MW, Malawi; SA, South Africa; ZA, South Africa; ZM, Zambia; ZW, Zimbabwe. ND, indicates not done. The neutralizing antibody titer (IC50) is defined
as the reciprocal of the plasma dilution that produces a 50% inhibition in target cell infection. A dash indicates no significant neutralization. For this assay, virus
neutralization was considered significant if the neutralization titers were at least 3-fold greater than those observed against the control pseudotype virus, aMLV. The
positive control was an HIV+ sera (N16).
doi:10.1371/journal.pone.0012076.t004
Table 5. Neutralization of clade C and B viruses in the TZM-bl neutralization assay by antibodies to rgp120.
Antisera
Virus Clade ZM651 N98025 IN98026 TN97008 ZA97002 TZ97005 CN98005 ZA97010 CN97001 ZA97012 NGPS 4E10
SA123.6 C - - - - - 62 87 - 103 - ,20 0.2
SA151.2 C - - - - - - - - - - ,20 0.4
SA156.12 C - 83 77 - - - - - - - ,20 0.43
SA172.17 C 69 64 146 88 86 117 - - 160 - 24 0.03
ZM233M.PB6 C - - 98 - - - - - 133 - 22 0.61
ZM197M.PB7 C - - - - - - - - - - ,20 0.1
MN B - - 2958 2935 626 - 2120 1357 38225 - ,20 0.04
SF162.LS B 319 - 3536 6714 517 1351 2671 3320 12705 89 ,20 0.40
Virus neutralization titers were measured by the TZM-bl neutralization assay [28]. Virus designations include the country of origin as follows: BR, Brazil; CN, China; IN,
India; MW, Malawi; SA, South Africa; ZA, South Africa; ZM, Zambia; ZW, Zimbabwe. ND, indicates not done. The neutralizing antibody titer (IC50) is defined as the
reciprocal of the plasma dilution that produces a 50% inhibition in target cell infection. A dash indicates no significant neutralization. For this assay, neutralization titers
were considered significant if they were 3-fold greater than the titers obtained for each virus pseudotype with normal guinea pig serum (NGPS). The positive control
was the 4E10 broadly neutralizing monoclonal antibody.
doi:10.1371/journal.pone.0012076.t005
Clade C gp120 Immunogenicity
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Production of antigens
A collection of ten clade C envelope genes with diverse
sequences was assembled for this study. Nine of these were PCR
amplified from infected cell lysates provided by Dr. S. Osmanov
(WHO-UNAIDS, Geneva, Switzerland) and one (ZM651) was
provided by Dr. F. Gao (Duke University, Durham, NC). In order
to produce antigens homologous to those used in the RV144
vaccine trial, codon optimized rgp120 sequences were expressed as
fusion proteins where the signal sequence and 12 amino acids from
the mature N-terminus of rgp120 were deleted, and replaced with
the signal sequence and 27 N-terminal amino acids of the mature
form of herpes simplex virus type 1 glycoprotein D (gD-1) as
described previously [26]. The resulting constructs were cloned
into a pCI based expression vector (Promega Corp, Madison, WI)
and expressed in Lipofectamine Plus (Invitrogen, Carlsbad, CA)
transfected 293 cells. Recombinant envelope proteins were
purified from growth conditioned cell culture media and subjected
to immunoaffinity chromatography, using a monoclonal antibody
specific for the HSV-1 flag epitope.
Guinea pig immunizations
Immunization studies (approval number 10245) were carried
out at Covance Research Products (Denver, PA), an AAALAC
accredited organization (OLAW assurance number:A3850-01;
USDA research registration number:23-R-007). The study was
reviewed and approved by the CRP’s Institutional Animal Care
and Use Committee (IACUC). Each purified protein was then
used to immunize groups of 6 guinea pigs. Each animal received
10mg of rgp120 on Days 0, 14, and 42. All antigens were
formulated in QS21 adjuvant that had previously demonstrated a
substantial dose-sparing ability as well as eliciting a strong
immune response [15]. Sera collected 2 weeks after the final
boost from each group were pooled and tested in antibody
binding assays.
Antibody binding assays
Antibody binding to rgp120 from homologous and heterologous
rgp120 by ELISA as described previously [5,7,14]. Antibody
binding assays were carried out with pooled sera from the 7
animals in each group immunized with rgp120 from different
strains of HIV. Antibody binding to synthetic peptides from the
V3 domain of rgp120 was carried out as described previously
[7,27]. A listing of the V3 peptides used in this study is provided in
Table S1. The ability of anti-rgp120 antibodies to block the
binding of rgp120 to CD4 from homologous and heterologous
strains of virus was measured in an ELISA assay similar to that
described previously [27].
Virus neutralization assays
The ability of antibodies to rgp120 to neutralize various
strains of HIV was measured in two different assays that made
u s eo fp s e u d o t y p ev i r u s e s .T h ef i r s ta s s a y( U 8 7p s e u d o t y p ea s s a y )
was performed by Monogram Biosciences (S. San Francisco, CA)
and utilized a panel of 10 heterologous clade C viruses and 4
clade B viruses. In this assay, pseudotype viruses prepared in
293 cells were used to infect U87 cells transfected with CD4
and either the CXCR4 or CCR5 chemokine receptors [18,19].
The second assay (TZM-bl assay) was carried out by Dr. D.
Montefiori (Duke Medical School) and utilized the TZM-bl assay
format [12,28]. This assay included 6 clade C viruses and 2 clade
Bv i r u s e s .
Phylogenetic analysis
Phylogenetic trees were constructed in EMBOSS http://www.
ebi.ac.uk .ac.uk using the neighbor joining method [29] by per-
centage identity, on sequences pre-aligned using the MAFFT
algorithm [30].
Supporting Information
Figure S1 Alignment of subtype C gp120 amino acid sequences.
Amino acid sequences were deduced from the DNA sequences of
the 10 subtype C gp120 genes. The sequences were aligned using
the MacVector Sequence Analysis package (Accelrys Inc. San
Diego, CA). The alignment was then edited manually to align
significant features, e.g. a pair of conserved N-linked glycosylation
sites in the V1 hypervariable region. Bases that match the con-
sensus of the aligned sequences are boxed. The sequence of HXB2
was included as a reference.
Found at: doi:10.1371/journal.pone.0012076.s001 (0.61 MB
PDF)
Figure S2 Phylogenetic analysis of gp120. Phylogenetic rela-
tionships between the 10 subtype C gp120 genes selected for
expression studies and 12 clade C genes from standard reference
panels. Ten clade C genes were obtained from the UNAIDS and
NIAID Networks for HIV Isolation and characterization. These
included: ZA97002.7-7, ZA9710, ZA9712, CN97001, CN98005,
IN98025, IN98026, TZ97005, TZ97008, ZM651. These were
compared to 12 envelope genes from the subtype C reference
panel of Li et al. [12] and 3 clade C reference sequences from the
Los Alamos sequence database www.hiv.lanl.gov/.webloc. The
tree was constructed in EMBOSS http://www.ebi.ac.uk using
the neighbor joining method [29] by percentage identity, on
sequences pre-aligned using the MAFFT algorithm [30]. Hori-
zontal lengths are proportional to distance, vertical distances are
for clarity only.
Found at: doi:10.1371/journal.pone.0012076.s002 (0.04 MB
PDF)
Figure S3 V3 PhylogeneticTree. Phylogenetic relationships
between the the V3 domains of 10 subtype C gp120 genes
selected for expression studies and the V3 domains of 12 clade C
genes from standard reference panels. Ten clade C genes were
obtained from the UNAIDS and NIAID Networks for HIV
Isolation and characterization. These included: ZA97002.7-7,
ZA9710, ZA9712, CN97001, CN98005, IN98025, IN98026,
TZ97005, TZ97008, ZM651. These were compared to 12
envelope genes from the subtype C reference panel of Li et al.
[12] and 3 clade C reference sequences from the Los Alamos
sequence database www.hiv.lanl.gov/.webloc. The tree was
constructed in EMBOSS http://www.ebi.ac.uk using the neighbor
joining method [29] by percentage identity, on sequences pre-
aligned using the MAFFT algorithm [30]. Horizontal lengths are
proportional to distance, vertical distances are for clarity only.
Found at: doi:10.1371/journal.pone.0012076.s003 (0.05 MB
PDF)
Figure S4 Binding of antisera against subtype C gp120s to
envelope proteins from clade C, B, E, and D viruses. ELISA plates
were coated with the gp120 from subtype C (ZM651), B (MN), E
(A244) or D (Z6). Pooled antisera raised against subtype C gp120s
indicated were incubated at a single dilution (1:5000), allowed to
bind, then detected using an HRP-labeled anti-guinea pig
antibody. OD490 for a single dilution is shown. The data bars
are color coded and correspond to the following strains: ZM1,
ZM651; IN1, IN98025; IN2, IN98026; TZ2, TZ97008; ZA1,
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CN97001; ZA3, ZA97012.
Found at: doi:10.1371/journal.pone.0012076.s004 (0.11 MB
PDF)
Table S1 Sequence of V3 peptides used in ELISA. The
sequence of V3 peptides from the MN (clade B) and A244 (clade
E) strains of HIV are indicated, along with the sequences of
peptides synthesized based on consensus sequences from clade A,
C and D envelope proteins. The clade C consensus sequence
matched that of the ZM651, CN97001, CN97005, and IN98026
strains of HIV. The IN1, TZ1, ZA1/ZA2, and ZA3 peptides
matched the sequences of the IN98025, TZ97005, ZA97002, and
ZA97012 envelopes, respectively. The consensus clade A V3
peptide matched that found in the TZ97008 isolate.
Found at: doi:10.1371/journal.pone.0012076.s005 (0.08 MB
PDF)
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